Careers  |  Sign In  |  Register  |   Twitter

Merck Purchases Rights to NewLink Ebola Vaccine

According to Reuters, Merck & Co. will buy worldwide commercial rights to rVSV-EBOV, the experimental Ebola vaccine produced by NewLink Genetics Corp. The drug, which was initially developed by the Public Health Agency of Canada, is being tested by the National Institutes of Health with results of a vaccine trial expected in early 2015.

Read the article published by Reuters.